CARLSBAD, Calif.--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, ...
In the latest quarter, 7 analysts provided ratings for Lineage (NASDAQ: LINE ), showcasing a mix of bullish and bearish perspectives. In the table below, you'll find a summary of their recent ratings, ...
Multiple analysts initiated Buy ratings on Lineage, citing its strong acquisition track record and technological investments. Analysts project high single-digit growth in AFFO and EBITDA for Lineage ...
CARLSBAD, Calif.--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, ...
CARLSBAD, Calif.--(BUSINESS WIRE)-- Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results